GoodRx is teaming up with Eli Lilly and Company to widen US access to a newly FDA-approved oral GLP-1 obesity treatment, Foundayo (orforglipron), launching a new cash-pay option aimed at patients outside traditional insurance coverage.
Eligible self-pay patients will be able to access Foundayo through GoodRx at a starting price of $149 per month—aligned with the lowest available discounted cash price at launch. The rollout includes nationwide pharmacy access, positioning the treatment as a more transparent, direct pathway to one of the most anticipated weight-management therapies.
Alongside the oral drug launch, GoodRx is also expanding access to Zepbound (tirzepatide) KwikPen, which will be available to eligible self-pay patients starting at $299 per month across more than 70,000 pharmacies nationwide. Together, the two offerings broaden access to both oral and injectable GLP-1 therapies for adults pursuing prescribed obesity care outside insurance systems.
“We’re excited to work with Lilly to help bring one of the most anticipated innovations in weight management to patients,” said Wendy Barnes, President and CEO of GoodRx.
“As new GLP-1 therapies continue to expand, including oral options like Foundayo, it is critical that access evolves alongside innovation. By pairing transparent cash pricing with nationwide pharmacy access and integrated care, we are helping ensure more people understand their options and more easily start treatment.”
“The launch of Foundayo reflects Lilly’s continued commitment to expanding treatment options for people living with obesity and advancing meaningful innovation in this category,” said Laura Steele, Group Vice President of US Cardiometabolic Health at Eli Lilly and Company. “We're committed to expanding access to treatment options through channels that meet patients where they are in their journey.”
The partnership highlights a broader shift in drug commercialization strategies, as manufacturers and platforms increasingly lean on direct-to-consumer models for high-demand therapies—particularly GLP-1 drugs, where insurance coverage can be limited or inconsistent.
GoodRx says its role is to bridge that gap by pairing discounted cash pricing with nationwide pharmacy access, enabling patients to initiate treatment more easily while maintaining continuity with their preferred pharmacy and care providers.
